Sun Pharma Presents New Data Highlighting Efficacy and Safety of Dermatology Treatments at EADV Congress

Sun Pharmaceutical Industries Limited (Sun Pharma) announced new data highlighting the efficacy and safety of its dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) Congress held in Amsterdam, Netherlands from September 25-28, 2024.

Three abstracts, accepted for podium and poster presentation, highlighted clinical efficacy and safety data for LEQSELVI™ (deuruxolitinib) 8 mg tablets. LEQSELVI is an oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2 approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with severe alopecia areata (AA).

Key findings from the presented data include:

*

Improved Hair Satisfaction:

Over 95% of patients taking deuruxolitinib 8 mg twice a day showed improvement in their hair satisfaction scores, compared to baseline over the 24-week period. This is significant considering that many individuals with AA experience depression and anxiety due to the visible nature of the disease.
*

Clinical Improvement in Depression and Anxiety:

The data demonstrated clinically meaningful improvements in anxiety and depression among patients taking deuruxolitinib to treat their severe AA.
*

Dose Optimization:

Results showed greater response with 8 mg tablets twice-daily as compared to higher once-daily dosing.

“Deuruxolitinib targets the immune mechanisms behind alopecia areata, providing patients with an effective treatment option,” said Arash Mostaghimi, MD, MPA, MPH, FAAD, Vice Chair, Clinical Trials and Innovation and Director, Inpatient Dermatology, Brigham and Women’s Hospital. “As a dermatologist, I find these data particularly encouraging because it addresses the physical effects of hair loss, which can, in turn, address the significant emotional and mental health challenges that patients often face.”

In addition to the data on LEQSELVI, Sun Pharma also presented 12 posters showcasing the clinical efficacy and safety of ILUMYA® (tildrakizumab) in moderate-to-severe plaque psoriasis. These data included research from interim data analysis from real-world settings.

These presentations at EADV provide valuable insights into the ongoing research and development of Sun Pharma’s dermatology portfolio. The company continues to invest in innovative treatments that offer hope and effective solutions for patients with various skin conditions.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top